IL117518A - The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease - Google Patents

The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease

Info

Publication number
IL117518A
IL117518A IL11751896A IL11751896A IL117518A IL 117518 A IL117518 A IL 117518A IL 11751896 A IL11751896 A IL 11751896A IL 11751896 A IL11751896 A IL 11751896A IL 117518 A IL117518 A IL 117518A
Authority
IL
Israel
Prior art keywords
chf
pharmaceutical compositions
treatment
preparation
heart failure
Prior art date
Application number
IL11751896A
Other languages
English (en)
Hebrew (he)
Other versions
IL117518A0 (en
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of IL117518A0 publication Critical patent/IL117518A0/xx
Priority to IL13541600A priority Critical patent/IL135416A0/xx
Publication of IL117518A publication Critical patent/IL117518A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11751896A 1995-03-17 1996-03-17 The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease IL117518A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL13541600A IL135416A0 (en) 1995-03-17 2000-04-02 The use of an aminotetralin derivative in the preparation of pharmaceutical compositions for the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI000532A IT1275935B1 (it) 1995-03-17 1995-03-17 Derivato di aminotetralina per la terapia di malattie cardiovascolari

Publications (2)

Publication Number Publication Date
IL117518A0 IL117518A0 (en) 1996-07-23
IL117518A true IL117518A (en) 2001-05-20

Family

ID=11370947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11751896A IL117518A (en) 1995-03-17 1996-03-17 The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease

Country Status (31)

Country Link
US (2) US6013678A (ru)
EP (2) EP0814791B1 (ru)
JP (1) JPH11502211A (ru)
KR (1) KR100391143B1 (ru)
CN (1) CN1112920C (ru)
AT (1) ATE218856T1 (ru)
AU (1) AU702656B2 (ru)
BR (1) BR9607996A (ru)
CA (1) CA2215671A1 (ru)
CZ (1) CZ288488B6 (ru)
DE (1) DE69621786T2 (ru)
DK (1) DK0814791T3 (ru)
EA (1) EA000937B1 (ru)
EE (1) EE04040B1 (ru)
ES (1) ES2177769T3 (ru)
HK (2) HK1004802A1 (ru)
HU (1) HUP9801686A3 (ru)
IL (1) IL117518A (ru)
IT (1) IT1275935B1 (ru)
LT (1) LT4355B (ru)
LV (1) LV11882B (ru)
MX (1) MX9706971A (ru)
NO (1) NO317402B1 (ru)
NZ (1) NZ303993A (ru)
PL (1) PL183347B1 (ru)
PT (1) PT814791E (ru)
SI (1) SI9620036B (ru)
SK (1) SK282952B6 (ru)
TR (1) TR199700963T1 (ru)
WO (1) WO1996029065A2 (ru)
ZA (1) ZA962073B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2695157B2 (ja) * 1986-12-29 1997-12-24 松下電器産業株式会社 可変パイプラインプロセッサ
WO2000076544A1 (en) * 1996-03-13 2000-12-21 Chiesi Farmaceutici S.P.A. Aminotetralin derivative for the therapy of cardiovascular diseases
SI1183046T1 (en) * 1999-06-09 2004-02-29 Chiesi Farmaceutici S.P.A. Aminotetralin derivative for the therapy of cardiovascular diseases
MXPA01012638A (es) * 1999-06-09 2002-07-22 Chiesi Farma Spa Derivados de aminotetralina para la terapia de enfermedades cardiovasculares.
IT1313583B1 (it) * 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
IL152751A0 (en) * 2000-05-12 2003-06-24 Chiesi Farma Spa Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
EP1384708A1 (en) * 2002-07-26 2004-01-28 CHIESI FARMACEUTICI S.p.A. Process for the manufacture of form I of nolomirole hydrochloride
US20050101668A1 (en) * 2003-07-24 2005-05-12 Chiesi Farmaceutici S.P.A. Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134997A (en) * 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
SU998342A1 (ru) 1981-12-11 1983-02-23 Предприятие П/Я А-3732 Способ получени синтетического цеолита типа @
IT1218322B (it) * 1982-06-10 1990-04-12 Chiesi Farma Spa Derivati di 1,2,3,4-tetraidronaftalene,procedimento di preparazione e relative composizioni farmaceutiche

Also Published As

Publication number Publication date
LT4355B (lt) 1998-06-25
PL183347B1 (pl) 2002-06-28
DK0814791T3 (da) 2002-10-07
DE69621786D1 (de) 2002-07-18
EP0814791A1 (en) 1998-01-07
EP0814791B1 (en) 2002-06-12
LT97147A (en) 1998-02-25
ATE218856T1 (de) 2002-06-15
TR199700963T1 (xx) 1998-02-21
EE9700231A (et) 1998-04-15
HUP9801686A3 (en) 1999-10-28
ZA962073B (en) 1996-11-27
SK125497A3 (en) 1998-02-04
US6103760A (en) 2000-08-15
CZ286697A3 (cs) 1998-03-18
CZ288488B6 (en) 2001-06-13
CA2215671A1 (en) 1996-09-26
WO1996029065A2 (en) 1996-09-26
KR100391143B1 (ko) 2003-11-28
EA199700243A1 (ru) 1998-02-26
EE04040B1 (et) 2003-06-16
NZ303993A (en) 2000-12-22
NO974267L (no) 1997-11-07
ITMI950532A0 (it) 1995-03-17
LV11882B (en) 1998-03-20
SK282952B6 (sk) 2003-01-09
SI9620036A (sl) 1998-02-28
PL322284A1 (en) 1998-01-19
SI9620036B (sl) 2002-10-31
ES2177769T3 (es) 2002-12-16
ITMI950532A1 (it) 1996-09-17
IT1275935B1 (it) 1997-10-24
BR9607996A (pt) 1998-06-23
HK1004802A1 (en) 1998-12-11
JPH11502211A (ja) 1999-02-23
AU5107296A (en) 1996-10-08
EP1216702A2 (en) 2002-06-26
CN1181699A (zh) 1998-05-13
PT814791E (pt) 2002-10-31
WO1996029065A3 (en) 1996-11-28
DE69621786T2 (de) 2003-01-02
NO974267D0 (no) 1997-09-16
NO317402B1 (no) 2004-10-25
KR19980703030A (ko) 1998-09-05
MX9706971A (es) 1997-11-29
CN1112920C (zh) 2003-07-02
AU702656B2 (en) 1999-02-25
HK1048060A1 (zh) 2003-03-21
LV11882A (lv) 1997-12-20
HUP9801686A2 (hu) 1999-06-28
US6013678A (en) 2000-01-11
IL117518A0 (en) 1996-07-23
EA000937B1 (ru) 2000-06-26
EP1216702A3 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
US20080287344A1 (en) Use of Amino Acids for Making Medicines for Treating Insulin Resistance
EP0814791B1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
Om Cardiovascular complications of cocaine
AU766230B2 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
Nademanee Cardiovascular effects and toxicities of cocaine
Aronson et al. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoilurane anesthesia
WO2000076544A1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
JP2001507006A (ja) 糖尿病性血管機能不全の予防のための薬剤の製造へのcomt阻害剤の使用
EP1331004A2 (en) Aminotetralin Derivative for the Therapy of Cardiovascular Diseases
Bevan et al. P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF).
Bevan et al. P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF).
Manolis et al. 4 Cardiovascular Agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees